#biotech
Related Stories (3)
Heart drug developer Kardigan targets $1.4 billion valuation in US IPO - Reuters
Heart drug developer Kardigan targets $1.4 billion valuation in US IPO Reuters
June 11, 2026Exclusive: Merck, rivals eye deal for Inhibrx experimental cancer drug tied to Keytruda, sources say - Reuters
Exclusive: Merck, rivals eye deal for Inhibrx experimental cancer drug tied to Keytruda, sources say Reuters
April 22, 2026Merck nears $6 billion acquisition of Terns Pharma to boost cancer portfolio, FT reports - Reuters
Merck nears $6 billion acquisition of Terns Pharma to boost cancer portfolio, FT reports Reuters
March 25, 2026